ANDA 216019, held by Pharmadax. Nifedipine.
As of Nov 16, 2026, ANDA 216019 (Nifedipine), held by Pharmadax, was first approved by FDA on Nov 18, 2022, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 18, 2022 | Original application | Approved | None posted |
| Nifedipine30MG · tablet, extended release;oral | Nifedipine | Discontinued |
| Nifedipine60MG · tablet, extended release;oral | Nifedipine | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters